IMR Press / FBL / Volume 12 / Issue 6 / DOI: 10.2741/2209

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article

Cytoplasmic binding partners of the platelet integrin αIIbβ3

Show Less
1 Department of Biological Sciences, Newark, DE, USA
2 Delaware Biotechnology Institute, Newark, DE, USA
3 Department of Biochemistry and Chemistry, University of Delaware, Newark, DE, USA
4 Department of Chemical Engineering, University of Delaware, Newark, DE, USA
Front. Biosci. (Landmark Ed) 2007, 12(6), 2038–2049; https://doi.org/10.2741/2209
Published: 1 January 2007
Abstract

Platelets function physiologically in mediating hemostasis, but are also associated with many pathological conditions, such as thrombosis, which can lead to myocardial infarction and/or stroke. Therefore, the study of platelet regulation and signaling has been of great interest and is necessary for generating effective anti-platelet therapeutics. One platelet signaling molecule of particular interest is the integrin  αIIbβ3, which binds Fg and mediates platelet cross-linking. The integrin itself as well as cytoplasmic proteins that interact with  αIIbβ3 have become potential targets for anti-platelet therapies. One such protein that has been shown to directly regulate  αIIbβ3 function is calcium- and integrin-binding protein 1 (CIB1). CIB1 has been implicated in  αIIbβ3 activation and outside-in signaling through the integrin. By increasing our understanding of CIB1 and other proteins that like it, associate with integrin  αIIbβ3, and the signaling events that result from those interactions, we may bring ourselves closer to more effective therapies. In the present work, we explore known cytoplasmic binding partners of the integrin  αIIbβ3 and their effect on  αIIbβ3, focusing on CIB1.

Share
Back to top